Development of new method to enrich human iPSC-derived renal progenitors using cell surface markers

Azusa Hoshina, Tatsuya Kawamoto, Shin Ichi Sueta, Shin Ichi Mae, Toshikazu Araoka, Hiromi Tanaka, Yasunori Sato, Yukiko Yamagishi, Kenji Osafune

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Cell therapy using renal progenitors differentiated from human embryonic stem cells (hESCs) or induced pluripotent stem cells (hiPSCs) has the potential to significantly reduce the number of patients receiving dialysis therapy. However, the differentiation cultures may contain undifferentiated or undesired cell types that cause unwanted side effects, such as neoplastic formation, when transplanted into a body. Moreover, the hESCs/iPSCs are often genetically modified in order to isolate the derived renal progenitors, hampering clinical applications. To establish an isolation method for renal progenitors induced from hESCs/iPSCs without genetic modifications, we screened antibodies against cell surface markers. We identified the combination of four markers, CD9 - CD140a + CD140b + CD271 + , which could enrich OSR1 + SIX2 + renal progenitors. Furthermore, these isolated cells ameliorated renal injury in an acute kidney injury (AKI) mouse model when used for cell therapy. These cells could contribute to the development of hiPSC-based cell therapy and disease modeling against kidney diseases.

Original languageEnglish
Article number6375
JournalScientific reports
Volume8
Issue number1
DOIs
Publication statusPublished - 2018 Dec 1
Externally publishedYes

Fingerprint

Stem Cells
Kidney
Cell- and Tissue-Based Therapy
Induced Pluripotent Stem Cells
Kidney Diseases
Acute Kidney Injury
Dialysis
Antibodies
Human Embryonic Stem Cells
Therapeutics

ASJC Scopus subject areas

  • General

Cite this

Hoshina, A., Kawamoto, T., Sueta, S. I., Mae, S. I., Araoka, T., Tanaka, H., ... Osafune, K. (2018). Development of new method to enrich human iPSC-derived renal progenitors using cell surface markers. Scientific reports, 8(1), [6375]. https://doi.org/10.1038/s41598-018-24714-3

Development of new method to enrich human iPSC-derived renal progenitors using cell surface markers. / Hoshina, Azusa; Kawamoto, Tatsuya; Sueta, Shin Ichi; Mae, Shin Ichi; Araoka, Toshikazu; Tanaka, Hiromi; Sato, Yasunori; Yamagishi, Yukiko; Osafune, Kenji.

In: Scientific reports, Vol. 8, No. 1, 6375, 01.12.2018.

Research output: Contribution to journalArticle

Hoshina, A, Kawamoto, T, Sueta, SI, Mae, SI, Araoka, T, Tanaka, H, Sato, Y, Yamagishi, Y & Osafune, K 2018, 'Development of new method to enrich human iPSC-derived renal progenitors using cell surface markers', Scientific reports, vol. 8, no. 1, 6375. https://doi.org/10.1038/s41598-018-24714-3
Hoshina, Azusa ; Kawamoto, Tatsuya ; Sueta, Shin Ichi ; Mae, Shin Ichi ; Araoka, Toshikazu ; Tanaka, Hiromi ; Sato, Yasunori ; Yamagishi, Yukiko ; Osafune, Kenji. / Development of new method to enrich human iPSC-derived renal progenitors using cell surface markers. In: Scientific reports. 2018 ; Vol. 8, No. 1.
@article{e833c0e070aa4d3298c333e66041218c,
title = "Development of new method to enrich human iPSC-derived renal progenitors using cell surface markers",
abstract = "Cell therapy using renal progenitors differentiated from human embryonic stem cells (hESCs) or induced pluripotent stem cells (hiPSCs) has the potential to significantly reduce the number of patients receiving dialysis therapy. However, the differentiation cultures may contain undifferentiated or undesired cell types that cause unwanted side effects, such as neoplastic formation, when transplanted into a body. Moreover, the hESCs/iPSCs are often genetically modified in order to isolate the derived renal progenitors, hampering clinical applications. To establish an isolation method for renal progenitors induced from hESCs/iPSCs without genetic modifications, we screened antibodies against cell surface markers. We identified the combination of four markers, CD9 - CD140a + CD140b + CD271 + , which could enrich OSR1 + SIX2 + renal progenitors. Furthermore, these isolated cells ameliorated renal injury in an acute kidney injury (AKI) mouse model when used for cell therapy. These cells could contribute to the development of hiPSC-based cell therapy and disease modeling against kidney diseases.",
author = "Azusa Hoshina and Tatsuya Kawamoto and Sueta, {Shin Ichi} and Mae, {Shin Ichi} and Toshikazu Araoka and Hiromi Tanaka and Yasunori Sato and Yukiko Yamagishi and Kenji Osafune",
year = "2018",
month = "12",
day = "1",
doi = "10.1038/s41598-018-24714-3",
language = "English",
volume = "8",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Development of new method to enrich human iPSC-derived renal progenitors using cell surface markers

AU - Hoshina, Azusa

AU - Kawamoto, Tatsuya

AU - Sueta, Shin Ichi

AU - Mae, Shin Ichi

AU - Araoka, Toshikazu

AU - Tanaka, Hiromi

AU - Sato, Yasunori

AU - Yamagishi, Yukiko

AU - Osafune, Kenji

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Cell therapy using renal progenitors differentiated from human embryonic stem cells (hESCs) or induced pluripotent stem cells (hiPSCs) has the potential to significantly reduce the number of patients receiving dialysis therapy. However, the differentiation cultures may contain undifferentiated or undesired cell types that cause unwanted side effects, such as neoplastic formation, when transplanted into a body. Moreover, the hESCs/iPSCs are often genetically modified in order to isolate the derived renal progenitors, hampering clinical applications. To establish an isolation method for renal progenitors induced from hESCs/iPSCs without genetic modifications, we screened antibodies against cell surface markers. We identified the combination of four markers, CD9 - CD140a + CD140b + CD271 + , which could enrich OSR1 + SIX2 + renal progenitors. Furthermore, these isolated cells ameliorated renal injury in an acute kidney injury (AKI) mouse model when used for cell therapy. These cells could contribute to the development of hiPSC-based cell therapy and disease modeling against kidney diseases.

AB - Cell therapy using renal progenitors differentiated from human embryonic stem cells (hESCs) or induced pluripotent stem cells (hiPSCs) has the potential to significantly reduce the number of patients receiving dialysis therapy. However, the differentiation cultures may contain undifferentiated or undesired cell types that cause unwanted side effects, such as neoplastic formation, when transplanted into a body. Moreover, the hESCs/iPSCs are often genetically modified in order to isolate the derived renal progenitors, hampering clinical applications. To establish an isolation method for renal progenitors induced from hESCs/iPSCs without genetic modifications, we screened antibodies against cell surface markers. We identified the combination of four markers, CD9 - CD140a + CD140b + CD271 + , which could enrich OSR1 + SIX2 + renal progenitors. Furthermore, these isolated cells ameliorated renal injury in an acute kidney injury (AKI) mouse model when used for cell therapy. These cells could contribute to the development of hiPSC-based cell therapy and disease modeling against kidney diseases.

UR - http://www.scopus.com/inward/record.url?scp=85045885195&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045885195&partnerID=8YFLogxK

U2 - 10.1038/s41598-018-24714-3

DO - 10.1038/s41598-018-24714-3

M3 - Article

C2 - 29686294

AN - SCOPUS:85045885195

VL - 8

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 6375

ER -